drugset
drugset / Trial / NCT05599880

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

NCT05599880 ↗

Phase 2 Recruiting 29 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia

Timeline

Start
2023-07-07
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Intravenous

Indications

autoimmune thrombocytopenia